The Efficacy and Safety of a Cap-Dependent Endonuclease Inhibitor, TG-1000, in Adolescent and Adult Outpatients with Acute Uncomplicated Influenza: A Multicenter, Randomized, Placebo-Controlled Phase III Trial
Fang Jin(Qingdao University), Nanshan Zhong(State Key Laboratory of Respiratory Disease), Chongyang Duan(Southern Medical University), Junyan Hu(Scripps Research Institute), Yufeng Luo(Huizhou Central People's Hospital), Hong Wang(Macau University of Science and Technology), Yu Xiong(Obstetrics and Gynecology Hospital of Fudan University), Juan Yuan(First Affiliated Hospital of Henan University), Feng Ye(Fujian Medical University), Yilan Sun(Zhejiang Provincial People's Hospital), Xuebing Yan(Nanjing Medical University), Yu Zhang(Kunming University of Science and Technology), Jinsai Shang, Xiexin Xu(Henan Polytechnic University), Banghan Ding(Guangdong Provincial Hospital of Traditional Chinese Medicine), Juan Huang(Guangzhou Electronic Technology (China)), Lin Chen(Shantou University)
Cited by 2
Related Papers
Correction: Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes
|Scientific Reports|2016|2.1k
Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection
|New England Journal of Medicine|2013|654
Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients
|Emerging Microbes & Infections|2020|535
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Voronoi-Based Multi-Robot Autonomous Exploration in Unknown Environments via Deep Reinforcement Learning
|IEEE Transactions on Vehicular Technology|2020|419